Here are a few more interesting tidbits about Bioamber’s demise and subsequent liquidation sale to LCYB.
"Likewise, the Sarnia
plant of BioAmber was bought by Taiwan-based LYC
Company. Later, they ramped up the plant operations
from 8000 MT/year to 18,000 MT/year in 2021 and are
expected to operate the plant at full capacity in the near
future [195]. BioAmber also shared its technical know-
how with Taiwan-based PTT–MCC, a JV of Mitsubishi
and PTT–PLC. They are using BioAmber’s SA fermen-
tation technology for PBS production. Presently, their
20,000 MT/year polybutylene succinate plant in Rayong,
Thailand, is using BioAmber’s fermentation technology
to produce bio-based SA, which is the starting feedstock
to produce this biopolymer."
"In 2018, BioAm-
ber declared bank-
ruptcy
• LCY Biosciences
Inc, a Taiwan-based
company acquired
this plant in 2018
and ramped up its
production capacity
from 8000 to 18,000
metric tons (MT)
"BioAmber,
initially a JV between New York-based Diversified Natu-
ral Products (DNP) and France-based ARD, was another
company that began largest commercial bio-SA produc-
tion in 2015, with proprietary acid-tolerant yeast, exclu-
sively licensed by Cargill. Jointly with Mitsui Japan, they
chose Canada’s Sarnia for its commercial operation, but
unfortunately they had to file for bankruptcy in 2018. The
failure of BioAmber’s Sarnia plant was a culmination of
several factors; for instance, the actual cost of the SA was
ten times higher than the predicted cost, the market of
SA was overestimated, and falling prices of petrochemi-
cal-based SA, the over-reliance on licensed technologies
rather than expanding their patent portfolio and not run-
ning the plant to its full capacity, as reviewed by Li and
Mupondwa [168]."
"The lesson must be
learned from the failure of BioAmber’s Sarnia plant,
which was primarly due to the overshooting of SA pro-
duction cost by ten times the estimated manufactur-
ing cost"
Market Data 
Markets 
AI
